Results

Most recent

AMD-Non-Neovascular

1–5 of 5 results for SIGLEC

Deactivation of CD163+ Retinal Macrophages With AVD-104 Siglec Agonism Can Restore Photoreceptor Function and Vision in Geographic Atrophy
Eleonora Lad, MD, PhD
Annual Meeting Talks
2025
Changes in Hyperautofluorescence Area and RPE/Outer Retinal Layer Thickness in the Phase 2a SIGLEC Study Assessing AVD-104 for the Treatment of GA
Carl D. Regillo, MD
Annual Meeting Talks
2025
Anatomic Changes Following a Single Injection of AVD-104 in Patients With GA Secondary to AMD in the SIGLEC Study
David S. Boyer, MD
Annual Meeting Talks
2024
Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Annual Meeting Talks
2024
Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024